FindMyKOL

Chi Lin, MD

Enriched profile

Professor and Vice Chair of Research, Department of Radiation Oncology, UNMC · University of Nebraska Medical Center

ORCID↗NPI↗
✓ Itemized profile
Region🇺🇸 Omaha, NE · Midwest · United StatesSpecialtyRadiation OncologyFocusAdvanced Radiotherapy Techniques+4
Active KOLFindMyKOL type: NationalLatest publication2024Online presenceNone verifiedPayments2021–2025NIH funding2022–2026

Chi Lin is Professor and Vice Chair of Research, Department of Radiation Oncology, UNMC at University of Nebraska Medical Center. OpenAlex indexes 219 publications with 3,021 citations (h-index 28); ClinicalTrials.gov lists 24 registered studies with this person as an investigator.

Data verified 26 Oct 2026

Overview

Updated 27 Oct 2026

Chi Lin, MD, is Professor and Vice Chair of Research, Department of Radiation Oncology, UNMC at University of Nebraska Medical Center. The public record shows 219 publications with 3,021 citations (h-index 28), centered on Advanced Radiotherapy Techniques, Pancreatic and Hepatic Oncology Research, Colorectal Cancer Surgical Treatments. It also documents an investigator role on 24 registered clinical trials, industry payments reported by 3 companies, 1 NIH-funded awards (2022–2026).

  • Most recent indexed publication: 2024 · Hepatic oncology
  • Top research focus: Advanced Radiotherapy Techniques
  • 24 registered trials on ClinicalTrials.gov
  • Open Payments reporting from 3 companies

Generated from the cited public record · current as of 27 Oct 2026. Every fact links its source below.

Indications focus

from trials led + research topics
Pancreatic Cancer4 trialsColorectal Cancer1 trialCarcinoma, Squamous Cell1 trialAnus Neoplasms1 trialHepatobiliary Cancer1 trialLiver Neoplasms1 trialLymphoma1 trialStroke1 trialEsophagitis1 trialCerebral Palsy1 trialParalysis1 trialThrombosis1 trialHematoma1 trialRectal Neoplasms1 trialBladder / Urothelial Cancer1 trialPain1 trialNeuro-Oncology / Glioma

Research focus

OpenAlex concept fingerprint
Advanced Radiotherapy TechniquesPancreatic and Hepatic Oncology ResearchColorectal Cancer Surgical TreatmentsEsophageal Cancer Research and TreatmentGlioma Diagnosis and Treatment

Works with

trial sponsors and companies reporting payments
University of NebraskaClinical trials6Industry payments—En-Chi ChiuClinical trials2Industry payments—Histosonics, Inc.Clinical trials—Industry payments2InnoPharmax Inc.Clinical trials2Industry payments—National Taiwan University HospitalClinical trials2Industry payments—Taichung Tzu Chi HospitalClinical trials2Industry payments—Taipei Medical University Shuang Ho HospitalClinical trials2Industry payments—Abbott LaboratoriesClinical trials—Industry payments1Avanos MedicalClinical trials—Industry payments1Belx Bio-Pharmaceutical (Taiwan) CorporationClinical trials1Industry payments—Cho Pharma Inc.Clinical trials1Industry payments—Coherus Oncology, Inc.Clinical trials1Industry payments—Kaohsiung Medical UniversityClinical trials1Industry payments—NRG OncologyClinical trials1Industry payments—PharmaEngineClinical trials1Industry payments—Standard Chem. & Pharm. Co., Ltd.Clinical trials1Industry payments—Tri-Service General Hospital (TSGH)Clinical trials1Industry payments—

Scholarship

indexed output and impact (OpenAlex)
View publications ↓
219publications

Distinct works indexed by OpenAlex, matched via ORCID; 10 in PubMed.

3,021citations

Total citations across indexed works.

28h-index

Hirsch index (OpenAlex). i10-index 72.

Clinical & industry

trials, payments and federal funding
24clinical trials

Investigator role on registered studies.

View trials ↓
3companies · 2021–2025

Companies reporting payments to CMS. Facts, not judgments.

View payments ↓
1NIH grants · 2022–2026

Federally funded research awards.

View funding ↓

Contact

The practice address and phone this provider lists in the federal NPPES (CMS) registry.

Practice address

Telephone

Practice address and telephone from the federal NPPES registry.

Sign in to view contact details →

Clinical trials

Updated 26 Oct 2026

Listed as an investigator on 24 registered studies on ClinicalTrials.gov. The most recent:

All 24 trial records: search, sort and filter.Explore →

Industry payments

Updated 26 Oct 2026

3 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:

View the CMS Open Payments record ↗

Medicare prescribing footprint (2021)

The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.

  • Nervous system

    100%
    Opioid Agonist100%
    Oxycodone Hcl100%
    Part D<11 patients
Where care is delivered (Part B)95.1% facility · 4.9% office

Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.

NIH funding

Updated 26 Oct 2026

1 NIH research award on record, funded 2022–2026 per NIH RePORTER. The latest:

All 41 award records: search, sort and filter.Explore →

Congress activity

Updated 26 Oct 2026

60 congress contributions (2009–2024) across AACR, ASCO, ASTRO, ESMO per OpenAlex. The most recent:

All 60 congress records: search, sort and filter.Explore →

Published abstracts are attributed via the same ORCID-disambiguated authorship as publications, so each is DOI-verified. Podium roles (invited talks, session chairs) and oral/poster type are added as program data is confirmed.

Publications

Updated 26 Oct 2026

Their five most recent publications, matched to their ORCID record and linked to PubMed.

All 10 publications: search, sort and filter.Explore →

Most-cited works

by citation count (OpenAlex)
  1. 01
    A Review and Update of Treatment Options and Controversies in the Management of Hepatocellular Carcinoma
    Article285 citations2016
    doi.org ↗
  2. 02
    Marital Status and Survival in Pancreatic Cancer Patients: A SEER Based Analysis
    Article178 citations2011
    doi.org ↗
  3. 03
    Biological determinants of radioresistance and their remediation in pancreatic cancer
    Article124 citations2017
    doi.org ↗
  4. 04
    Cancer in People Living With HIV, Version 1.2018, NCCN Clinical Practice Guidelines in Oncology
    Article104 citations2018
    doi.org ↗
  5. 05
    MUC1-Mediated Metabolic Alterations Regulate Response to Radiotherapy in Pancreatic Cancer
    Article96 citations2017
    doi.org ↗
All 219 cited works: search, sort and filter.Explore →

Network

Updated 26 Oct 2026

The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.

Michael J. Baine43Vivek Verma42Saber Amin23Dandan Zheng23Jane L. Meza20Weining Ken Zhen18Nathan Ronald Bennion18Abhijeet R. Bhirud17Mary E. Charlton17S. Zhou17C.A. Enke15Sicong Li13Andrew O. Wahl13Yu Lei12Charles B. Simone11Chandrakanth Are11Chi Zhang11Jean L. Grem10Quan P. Ly10Elizabeth A. Chrischilles9Richard L. Sleightholm9Jeffrey M. Ryckman9S. Chen9Kyle A. Denniston8Linjie Wei8Aaron R. Sasson8J Driewer7James K. Schwarz7Surinder K. Batra7Charles A. Enke7Elizabeth Ruby Lyden6Karyn Beth Stitzenberg6Jane Pendergast6Robert B. Wallace6Nan Zhao6Joshua J. Souchek6Thorvardur Ragnar Halfdanarson6Fei Wang6Chi Zhang6Fausto R. Loberiza6

Background & recognition

Updated 26 Oct 2026

Credentials, appointments and honors, newest first, each linked to the public source it came from.

Education

degrees and training on record
  • PhD

    Thomas Jefferson University

    1996
    verifiedCorroborated by FindMyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →nebraskamed.com ↗
  • MD

    Medical Center of Fudan University

    1983
    verifiedCorroborated by FindMyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →nebraskamed.com ↗
  • MD

    PhD, MS (listed as Chi Lin, MD, PhD, MS)

    verifiedCorroborated by FindMyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →unmc.edu ↗

Editorial & leadership roles

journal and society appointments
  • Member

    American Society for Therapeutic Radiology and Oncology

    verifiedCorroborated by FindMyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →unmc.edu ↗
  • Member

    American College of Radiation Oncology

    verifiedCorroborated by FindMyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →unmc.edu ↗
  • Member

    American Society of Clinical Oncology

    verifiedCorroborated by FindMyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →unmc.edu ↗
  • Member

    American College of Radiology

    verifiedCorroborated by FindMyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →unmc.edu ↗

Secondary affiliations

appointments beyond the home institution

Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.

Similar KOLs

Other experts from the same institution or the same specialty.